BAY 11-7082 ameliorates diabetic nephropathy by attenuating hyperglycemia-mediated oxidative stress and renal inflammation via NF-κB pathway

Environmental Toxicology and Pharmacology

Volumn 39, Issue 2, 2015, Pages 690-699

  Kolati, Sambasiva Rao ^a   Kasala, Eshvendar Reddy ^a   Bodduluru, Lakshmi Narendra ^a   Mahareddy, Jalandhar Reddy ^a   Uppulapu, Shravan Kumar ^a   Gogoi, Ranadeep ^a   Barua, Chandana C ^b   Lahkar, Mangala ^a,c  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b Uttar Pradesh Pandit Deen Dayal Upadhayay Pashu Chikitsa Vigyan Vishwavidyalay Evum Go Anusandhan Sansthan   (India)

^c GAUHATI MEDICAL COLLEGE   (India)

Author keywords

BAY 11 7082; Diabetic nephropathy; NF B; Oxidative stress; Renal inflammation; Streptozotocin

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; CREATININE; GLUCOSE; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; NITRIC OXIDE; NITROGEN; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UREA; 3-(4-METHYLPHENYLSULFONYL)-2-PROPENENITRILE; GLUCOSE BLOOD LEVEL; NITRILE; SULFONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HYPERGLYCEMIA; INHIBITION KINETICS; KIDNEY DYSFUNCTION; LIPID PEROXIDATION; MALE; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; UREA NITROGEN BLOOD LEVEL; WEIGHT REDUCTION; ANALYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DRUG EFFECTS; KIDNEY; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; HYPERGLYCEMIA; INTERLEUKIN-1BETA; INTERLEUKIN-6; KIDNEY; MALE; NF-KAPPA B; NITRILES; OXIDATIVE STRESS; RATS, SPRAGUE-DAWLEY; SULFONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84923044693     PISSN: 13826689     EISSN: 18727077     Source Type: Journal    
DOI: 10.1016/j.etap.2015.01.019     Document Type: Article

References (42)

1. Abe H., Matsubara T., Arai H., Doi T. Role of Smad1 in diabetic nephropathy: molecular mechanisms and implications as a diagnostic marker. Histol. Histopathol. 2011, 26:531-541.
2. Baig M.A., Gawali V.B., Patil R.R., Naik S.R. Protective effect of herbomineral formulation (Dolabi) on early diabetic nephropathy in streptozotocin-induced diabetic rats. J. Nat. Med. 2012, 66:500-509.
3. Baker R.G., Hayden M.S., Ghosh S. NF-κB, inflammation, and metabolic disease. Cell Metab. 2011, 13:11-22.
4. Barnes P.J., Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 1997, 336:1066-1071.
5. Burns N., Gold B. The effect of 3-methyladenine DNA glycosylase-mediated DNA repair on the induction of toxicity and diabetes by the beta-cell toxicant streptozotocin. Toxicol. Sci. 2007, 95:391-400.
6. Busch M., Franke S., Ruster C., Wolf G. Advanced glycation end-products and the kidney. Eur. J. Clin. Invest. 2010, 40:742-755.
7. Centers for Disease Control and Prevention: Press release: Number of Americans with diabetes projected to double or triple by 2050. Older, more diverse population and longer lifespans contribute to increase. 22 October 2010. Available from: [Accessed on 13.08.2014]. http://www.cdc.gov/media/pressrel/2010/r101022.html.
8. Chaudhry J., Ghosh N.N., Roy K., Chandra R. Antihyperglycemic effect of a new thiazolidinedione analogue and its role in ameliorating oxidative stress in alloxan-induced diabetic rats. Life Sci. 2007, 80:1135-1142.
9. Chen L., Zhang J., Zhang Y., Wang Y., Wang B. Improvement of inflammatory responses associated with NF-κB pathway in kidneys from diabetic rats. Inflamm. Res. 2008, 57:199-204.
10. Eberhardt W., Pfeilschifter J. Nitric oxide and vascular remodeling: spotlight on the kidney. Kidney Int. Suppl. 2007, 72:S9-S16.
11. Ellman G.L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 1959, 82:70-77.
12. Furuta T., Saito T., Ootaka T., Soma J., Obara K., Abe K., Yoshinaga K. The role of macrophages in diabetic glomerulosclerosis. Am. J. Kidney Dis. 1993, 21:480-485.
13. Galkina E., Ley K. Leukocyte recruitment and vascular injury in diabetic nephropathy. J. Am. Soc. Nephrol. 2006, 17:368-377.
14. Giacco F., Brownlee M. Oxidative stress and diabetic complications. Circ. Res. 2010, 107:1058-1070.
15. Gruden G., Setti G., Hayward A., Sugden D., Duggan S., Burt D., et al. Mechanical stretch induces monocyte chemoattractant activity via an NF-kappaB-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: inhibition by rosiglitazone. J. Am. Soc. Nephrol. 2005, 16:688-696.
16. Ha H., Yu M.R., Choi Y.J., Kitamura M., Lee H.B. Role of high glucose-induced nuclear factor-kappaB-activation in monocyte chemoattractant protein-1 expression by mesangial cells. J. Am. Soc. Nephrol. 2002, 13:894-902.
17. Hostetter T.H. Hypertrophy and hyperfunction of the diabetic kidney. J. Clin. Invest. 2001, 107:161-162.
18. Iwamoto M., Mizuiri S., Arita M., Hemmi H. Nuclear factor-kappaB activation in diabetic rat kidney: evidence for involvement of P-selectin in diabetic nephropathy. Tohoku J. Exp. Med. 2005, 206:163-171.
19. Karaagac N., Salman F., Dogru-Abbasoglu S., Uysal M. Changes in prooxidant-antioxidant balance in tissues of rats following long-term hyperglycemic status. Endocr. Res. 2011, 36:124-133.
20. Kedziora-Kornatowska K., Szram S., Kornatowski T., Szadujkis-Szadurski L., Kedziora J., Bartosz G. The effect of verapamil on the antioxidant defence system in diabetic kidney. Clin. Chim. Acta 2002, 322:105-112.
21. Kikkawa R., Koya D., Haneda M. Progression of diabetic nephropathy. Am. J. Kidney Dis. 2003, 41:S19-S21.
22. Kuhad A., Chopra K. Attenuation of diabetic nephropathy by tocotrienol: involvement of NFkB signaling pathway. Life Sci. 2009, 84:296-301.
23. Kumar A., Negi G., Sharma S.S. Suppression of NF-κB and NF-κB regulated oxidative stress and neuroinflammation by BAY 11-7082 (IκB phosphorylation inhibitor) in experimental diabetic neuropathy. Biochimie 2012, 94:1158-1165.
24. Lee F.T., Cao Z., Long D.M., Panagiotopoulos S., Jerums G., Cooper M.E., et al. Interactions between Angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J. Am. Soc. Nephrol. 2004, 15:2139-2151.
25. Lee J., Rhee M.H., Kim E., Cho J.Y. BAY 11-7082 is a broad-spectrum inhibitor with anti-inflammatory activity against multiple targets. Mediat. Inflamm. 2012, 2012.
26. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
27. Masiello P., Broca C., Gross R., Roye M., Manteghetti M., Hillaire-Buys D., et al. Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes 1998, 47:224-229.
28. Mezzano S., Aros C., Droguett A., Burgos M.E., Ardiles L., Flores C., et al. NF-κB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol. Dial. Transpl. 2004, 19:2505-2512.
29. Mora C., Navarro J.F. Inflammation and diabetic nephropathy. Curr. Diab. Rep. 2006, 6:463-468.
30. Mori N., Yamada Y., Ikeda S., Yamasaki Y., Tsukasaki K., Tanaka Y., et al. Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood 2002, 100:1828-1834.
31. Navarro J.F., Mora C. Role of inflammation in diabetic complications. Nephrol. Dial. Transpl. 2005, 20:2601-2604.
32. Navarro-González J.F., Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J. Am. Soc. Nephrol. 2008, 19:433-442.
33. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979, 95:351-358.
34. Oliveira M., Santos M.A., Pacheco M. Glutathione protects heavy metal-induced inhibition of hepatic microsomal ethoxyresorufin O-deethylase activity in Dicentrarchus labrax L. Ecotoxicol. Environ. Saf. 2004, 58:379-385.
35. Pfeilschifter J., Schwarzenbach H. Interleukin 1 and tumor necrosis factor stimulate cGMP formation in rat renal mesangial cells. FEBS Lett. 1990, 273:185-187.
36. Pierce J.W., Schoenleber R., Jesmok G., Best J., Moore S.A., Collins T., et al. Novel inhibitors of cytokine-induced I kappa B alpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J. Biol. Chem. 1997, 272:21096-21103.
37. Ruster C., Wolf G. The role of chemokines and chemokine receptors in diabetic nephropathy. Front. Biosci. 2007, 13:944-955.
38. Sanz A.B., Sanchez-Nino M.D., Ramos A.M., Moreno J.A., Santamaria B., Ruiz-Ortega M., et al. NF-κB in renal inflammation. J. Am. Soc. Nephrol. 2010, 21:1254-1262.
39. Sassy-Prigent C., Heudes D., Mandet C., Baélair M.-F., Michel O., Perdereau B., et al. Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 2000, 49:466-475.
40. Thomson S.C., Deng A., Bao D., Satriano J., Blantz R.C., Vallon V. Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes. J. Clin. Invest. 2001, 107:217-224.
41. Williams M.E., Tuttle K.R. The next generation of diabetic nephropathy therapies: an update. Adv. Chronic Kidney Dis. 2005, 12:212-222.
42. Zhao J., Zhang H., Huang Y., Wang H., Wang S., Zhao C., et al. Bay11-7082 attenuates murine lupus nephritis via inhibiting NLRP3 inflammasome and NF-κB activation. Int. Immunopharmacol. 2013, 17:116-122.